« Back to News

In the news

April 17, 2024

Startups probe hidden viruses in the 'dark genome' to treat disease |  Nature Biotechnology

April 2, 2024

Unlocking the Dark Genome for Lupus and Other Autoimmune Diseases |  Unseen Upside, a podcast by Cambridge Associates

March 12, 2024

Dark Genome Hunting with Rosana Kapeller and Marty Taylor |  Raising Health™, a podcast by a16z Bio+Health

November 13, 2023

Enara Bio, ROME Therapeutics and Nucleome Therapeutics Host 2nd Annual Dark Genome Symposium

October 12, 2023

ROME honored in BostInno 2023 Fire Awards |  BostInno

September 12, 2023

With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’ |  BioPharma Dive

September 12, 2023

Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma |  Endpoints News

August 4, 2023

"Biotech in Boston" Event Featuring Rosana Kapeller, ROME CEO |  Boston Business Journal

June 14, 2023

Rosana Kapeller Among "Disruptors" Featured on WMIF Panel |  World Medical Innovation Forum

June 8, 2023

Panel: Maximizing Platform Potential, with ROME CSO Dennis Zaller |  Longwood Healthcare Leaders Conference

June 7, 2023

BIO Panel on Oncology Drug Discovery Features ROME CSO Dennis Zaller |  BIO International Convention

May 10, 2023

Panel: Building Strong Relationships with Boards and Investors, featuring Rosana Kapeller |  Convergence Forum

March 1, 2023

Jumping Genes’ Role in Cancer  |  The Scientist

November 11, 2022

Podcast: Harnessing the Power of the Repeatome with Dennis Zaller |  Biotech2050 podcast

October 7, 2022

ROME CEO Rosana Kapeller Named to Forbes "50 Over 50" |  Forbes

September 22, 2022

ROME honored in Endpoints 11: The top private biotechs in pursuit of new drugs |  Endpoints News

May 3, 2022

The Mysterious Dark Genome: Panel Featuring Rosana Kapeller, CEO of ROME |  World Medical Innovation Forum

March 8, 2022

The "Dark Genome" with Dr. Rosana Kapeller-Lieberman |  GV "Theory and Practice" podcast

November 21, 2021

ROME Among C&EN’s 2021 10 Start-Ups to Watch |  C&EN

September 14, 2021

Kapeller's ROME bags $77M to strike gold in the backwaters of the genome |  Fierce Biotech

September 28, 2020

ROME Named to Fierce Biotech's 2020 Fierce 15 |  Fierce Biotech

September 10, 2020

Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry |  MassBio

August 20, 2020

Rome snags Merck, Celgene vet Zaller as new CSO |  Fierce Biotech

August 20, 2020

ROME founder Rosana Kapeller recruits a CSO from the senior ranks of a major league R&D team |  Endpoints News

August 17, 2020

Companies Strain to Outdo Each Other with Work-from-Home Perks (Think Ukuleles) |  Wall Street Journal

August 11, 2020

From Rio to Rome: Rosanna Kapeller on The Long Run |  The Timmerman Report

April 29, 2020

ROME: Tackling repeat DNA for cancer, autoimmunity |  BioCentury

April 28, 2020

At ROME Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs |  Xconomy

April 27, 2020

The Road to ROME's Series A |  GV

April 27, 2020

ROME Therapeutics launches to probe junk DNA for cancer drug discovery |  C&EN

April 27, 2020

ROME Therapeutics debuts with $50M and Rosana Kapeller at the helm |  Fierce Biotech

April 27, 2020

GV joins $50 million round in ROME Therapeutics to research ‘junk DNA’ for cancer therapies |  VentureBeat

April 27, 2020

Nimbus founder Rosana Kapeller has a new company, with $50M and an eye on the ‘repeatome’ |  Endpoints News